Tingsheng Medical Completes Nearly RMB 100 Million Series B+ Financing to Advance Development and Clinical Application of 4D Intracardiac Echocardiography (4D ICE)

Recently, Jiangsu TINGSN Technology Co., Ltd. (hereinafter referred to as "TINGSN") announced the completion of a nearly 100-million-yuan B+ round of financing. The funds from this round will further increase investment in the research and development and clinical application of 4D intracardiac echocardiography (4D ICE), in preparation for the upcoming mass production.

Jiangsu TINGSN Technology Co., Ltd. was established in 2017. The company focuses on technological innovation in the application of ultrasound for cardiac electrophysiology and structural heart disease. By integrating imaging, mapping, and ablation energy, it aims to provide more effective treatment for patients with heart diseases. Currently, the company's products under development include a 2D intracardiac echocardiography imaging system, a 4D intracardiac echocardiography imaging system, an ultrasound 3D mapping system, and an ultrasound energy therapy system.

Notably, TINGSN successfully completed China's first 4D ICE human clinical study on April 29. This breakthrough not only marks a critical leap for Chinese companies in the cardiovascular interventional imaging field, transitioning from "catching up" to "running alongside," but also demonstrates that TINGSN’s full-chain innovation system—from China's first domestically produced 2D ICE catheter to 4D ICE—has matured.

In 2024, the number of electrophysiology surgeries in China has exceeded 300,000, with a market size surpassing tens of billions. The global volume of structural heart surgeries is also growing rapidly. As clinical demand continues to expand, traditional 2D ICE has shown limitations in complex structural heart disease and electrophysiology procedures, making it difficult to meet practical application needs in some surgical scenarios. Against this backdrop, the clinical application value of 4D ICE based on ASIC chips is gradually being proven and strengthened. 4D ICE can be applied in all surgical scenarios where 2D ICE is used, and it can also provide precise imaging guidance in scenarios where 2D ICE falls short. The real-time three-dimensional cardiac imaging provided by 4D ICE for clinicians will bring an entirely new perspective for the industry, truly transitioning from two-dimensional to real-time three-dimensional imaging.

From the perspective of overseas development, 4D ICE is currently mainly applied in left atrial appendage closure, mitral valve repair surgery, tricuspid valve repair surgery, transcatheter aortic valve replacement surgery, atrial fibrillation radiofrequency ablation surgery, PFA ablation surgery, cryoablation surgery, and complex congenital heart disease surgeries. Additionally, for more complex procedures such as newly approved mitral and tricuspid valve replacement surgeries, 4D ICE has even greater potential. In the two major cardiovascular surgical scenarios—structural heart disease surgeries and electrophysiology surgeries—as terminal prices decrease, 4D ICE is expected to gradually replace 2D ICE and TEE to become the primary clinical imaging device. With dynamic four-dimensional imaging, 4D ICE helps operators quickly locate, reduces the risk of complications, enhances surgical safety, and provides a new solution for complex cardiac interventional procedures.

TINGSN CEO Dongyu Zhang stated: 4D ICE represents the pinnacle of cardiovascular interventional imaging technology. The team's successful development of this product and completion of the first human clinical trial within four years is due to TINGSN's solid foundation of underlying technology, sufficient R&D investment, and outstanding, efficient team execution. The successful development of 4D ICE has injected strong momentum into the company’s future growth, significantly enhancing its competitiveness in the global market. This marks a solid step forward for the team in achieving the vision of "becoming an influential Chinese medical device manufacturing brand."